Malaria Pipeline Insight
DelveInsight’s, “Malaria - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Malaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is preventable and curable. In 2019, there were an estimated 229 million cases of malaria worldwide. Malaria is caused by Plasmodium parasites. The parasites are spread to people through the bites of infected female Anopheles mosquitoes, called "malaria vectors." There are 5 parasite species that cause malaria in humans, and 2 of these species – P. falciparum and P. vivax – pose the greatest threat.
Malaria is an acute febrile illness. In a non-immune individual, symptoms usually appear 10–15 days after the infective mosquito bite. The first symptoms – fever, headache, and chills – may be mild and difficult to recognize as malaria. If not treated within 24 hours, P. falciparum malaria can progress to severe illness, often leading to death.
Early diagnosis and treatment of malaria reduces disease and prevents deaths. Antimalarial medicines can also be used to prevent malaria. For travelers, malaria can be prevented through chemoprophylaxis, which suppresses the blood stage of malaria infections, thereby preventing malaria disease. The most common antimalarial drugs include: Chloroquine phosphate, Chloroquine is the preferred treatment for any parasite that is sensitive to the drug.
The companies and academics are working to assess challenges and seek opportunities that could influence Malaria R&D. The therapies under development are focused on novel approaches for Malaria.
Malaria Emerging Drugs Chapters
This segment of the Malaria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Malaria Emerging Drugs
R21/Matrix M- the new vaccine candidate, is a modified version of RTS, S - another candidate against malaria by GlaxoSmithKline. This is designed with an aim to stop the malaria parasite- Plasmodium falciparum from entering the liver and preventing the subsequent deadly blood stages. The vaccine targets the liver stage protein of the parasite’s life cycle.
It is currently in Phase III stage of development for the treatment of Malaria and is being developed by GlaxoSmithKline.
KAF156 is the first compound to progress into clinical development from the novel imidazolopiperazine class of antimalarial molecules. A key strength of the drug is its potential to both treat and prevent malaria, including resistant strains. Phase IIa studies have demonstrated that KAF156 rapidly kills both P. vivax and P. falciparum malaria parasites.
It is currently in Phase II stage of development for the treatment of Malaria and is being developed by Novartis.
Further product details are provided in the report……..
Malaria: Therapeutic Assessment
This segment of the report provides insights about the different Malaria drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Malaria
There are approx. 20+ key companies which are developing the Malaria. The companies which have their Malaria drug candidates in the most advanced stage, i.e. Phase III include, GlaxoSmithKline.
DelveInsight’s report covers around 20+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Malaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Malaria: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Malaria therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malaria drugs.
Malaria Report Insights
- Malaria Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Malaria Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Malaria drugs?
- How many Malaria drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Malaria?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Malaria therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Malaria and their status?
- What are the key designations that have been granted to the emerging drugs?